Cargando…

Predictive value of p53, Ki67 and TLR5 in neoplastic progression of Barrett’s esophagus: a matched case–control study

Barrett’s esophagus progresses to high-grade dysplasia or cancer along the well-established metaplasia-dysplasia-adenocarcinoma sequence. The aim of this study was to evaluate the value of p53, Ki67, and toll-like receptor 5 (TLR5) in prediction of malignant progression of Barrett’s metaplasia and l...

Descripción completa

Detalles Bibliográficos
Autores principales: Helminen, Olli, Melkko, Jukka, Saarnio, Juha, Sihvo, Eero, Kuopio, Teijo, Ohtonen, Pasi, Kauppila, Joonas H., Karttunen, Tuomo J., Huhta, Heikki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485097/
https://www.ncbi.nlm.nih.gov/pubmed/35614270
http://dx.doi.org/10.1007/s00428-022-03340-5
_version_ 1784792016587063296
author Helminen, Olli
Melkko, Jukka
Saarnio, Juha
Sihvo, Eero
Kuopio, Teijo
Ohtonen, Pasi
Kauppila, Joonas H.
Karttunen, Tuomo J.
Huhta, Heikki
author_facet Helminen, Olli
Melkko, Jukka
Saarnio, Juha
Sihvo, Eero
Kuopio, Teijo
Ohtonen, Pasi
Kauppila, Joonas H.
Karttunen, Tuomo J.
Huhta, Heikki
author_sort Helminen, Olli
collection PubMed
description Barrett’s esophagus progresses to high-grade dysplasia or cancer along the well-established metaplasia-dysplasia-adenocarcinoma sequence. The aim of this study was to evaluate the value of p53, Ki67, and toll-like receptor 5 (TLR5) in prediction of malignant progression of Barrett’s metaplasia and low-grade dysplasia. This was a retrospective matched case–control study based on Northern and Central Finland population. Patients diagnosed with esophageal high-grade dysplasia or adenocarcinoma were included. From these patients, all previous endoscopy samples were obtained along with original diagnostic HE-slides and clinical data. Age- and sex-matched patients with non-progressing Barrett’s metaplasia and low-grade dysplasia confirmed with follow-up endoscopies were used as controls. Two gastrointestinal pathologist re-reviewed all original HE-slides, and newly made sections to confirm representative tissue material blinded from clinical data. p53, Ki67, and TLR5 were immunohistochemically stained. Final cohort included 45 patients with progressive Barrett’s metaplasia (n = 21) or low-grade dysplasia (n = 24), and 92 patients with non-progressive Barrett’s metaplasia (n = 52) or low-grade dysplasia (n = 40). In Barrett’s metaplasia, aberrant p53 expression was observed in 6% of samples in progressors and 0% in non-progressors. In low-grade dysplasia, aberrant p53 was seen in 56% of samples in progressors and 17% in non-progressors (Odd’s ratio 6.7, 95% CI 1.8–24.6). Ki67 or TLR5 showed no association with disease progression. In this matched case–control study, p53 expression associated with a high risk of malignant progression in Barrett’s low-grade dysplasia. Routine staining of p53 is indicated in expert confirmed low-grade dysplasia.
format Online
Article
Text
id pubmed-9485097
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-94850972022-09-21 Predictive value of p53, Ki67 and TLR5 in neoplastic progression of Barrett’s esophagus: a matched case–control study Helminen, Olli Melkko, Jukka Saarnio, Juha Sihvo, Eero Kuopio, Teijo Ohtonen, Pasi Kauppila, Joonas H. Karttunen, Tuomo J. Huhta, Heikki Virchows Arch Original Article Barrett’s esophagus progresses to high-grade dysplasia or cancer along the well-established metaplasia-dysplasia-adenocarcinoma sequence. The aim of this study was to evaluate the value of p53, Ki67, and toll-like receptor 5 (TLR5) in prediction of malignant progression of Barrett’s metaplasia and low-grade dysplasia. This was a retrospective matched case–control study based on Northern and Central Finland population. Patients diagnosed with esophageal high-grade dysplasia or adenocarcinoma were included. From these patients, all previous endoscopy samples were obtained along with original diagnostic HE-slides and clinical data. Age- and sex-matched patients with non-progressing Barrett’s metaplasia and low-grade dysplasia confirmed with follow-up endoscopies were used as controls. Two gastrointestinal pathologist re-reviewed all original HE-slides, and newly made sections to confirm representative tissue material blinded from clinical data. p53, Ki67, and TLR5 were immunohistochemically stained. Final cohort included 45 patients with progressive Barrett’s metaplasia (n = 21) or low-grade dysplasia (n = 24), and 92 patients with non-progressive Barrett’s metaplasia (n = 52) or low-grade dysplasia (n = 40). In Barrett’s metaplasia, aberrant p53 expression was observed in 6% of samples in progressors and 0% in non-progressors. In low-grade dysplasia, aberrant p53 was seen in 56% of samples in progressors and 17% in non-progressors (Odd’s ratio 6.7, 95% CI 1.8–24.6). Ki67 or TLR5 showed no association with disease progression. In this matched case–control study, p53 expression associated with a high risk of malignant progression in Barrett’s low-grade dysplasia. Routine staining of p53 is indicated in expert confirmed low-grade dysplasia. Springer Berlin Heidelberg 2022-05-26 2022 /pmc/articles/PMC9485097/ /pubmed/35614270 http://dx.doi.org/10.1007/s00428-022-03340-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Helminen, Olli
Melkko, Jukka
Saarnio, Juha
Sihvo, Eero
Kuopio, Teijo
Ohtonen, Pasi
Kauppila, Joonas H.
Karttunen, Tuomo J.
Huhta, Heikki
Predictive value of p53, Ki67 and TLR5 in neoplastic progression of Barrett’s esophagus: a matched case–control study
title Predictive value of p53, Ki67 and TLR5 in neoplastic progression of Barrett’s esophagus: a matched case–control study
title_full Predictive value of p53, Ki67 and TLR5 in neoplastic progression of Barrett’s esophagus: a matched case–control study
title_fullStr Predictive value of p53, Ki67 and TLR5 in neoplastic progression of Barrett’s esophagus: a matched case–control study
title_full_unstemmed Predictive value of p53, Ki67 and TLR5 in neoplastic progression of Barrett’s esophagus: a matched case–control study
title_short Predictive value of p53, Ki67 and TLR5 in neoplastic progression of Barrett’s esophagus: a matched case–control study
title_sort predictive value of p53, ki67 and tlr5 in neoplastic progression of barrett’s esophagus: a matched case–control study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485097/
https://www.ncbi.nlm.nih.gov/pubmed/35614270
http://dx.doi.org/10.1007/s00428-022-03340-5
work_keys_str_mv AT helminenolli predictivevalueofp53ki67andtlr5inneoplasticprogressionofbarrettsesophagusamatchedcasecontrolstudy
AT melkkojukka predictivevalueofp53ki67andtlr5inneoplasticprogressionofbarrettsesophagusamatchedcasecontrolstudy
AT saarniojuha predictivevalueofp53ki67andtlr5inneoplasticprogressionofbarrettsesophagusamatchedcasecontrolstudy
AT sihvoeero predictivevalueofp53ki67andtlr5inneoplasticprogressionofbarrettsesophagusamatchedcasecontrolstudy
AT kuopioteijo predictivevalueofp53ki67andtlr5inneoplasticprogressionofbarrettsesophagusamatchedcasecontrolstudy
AT ohtonenpasi predictivevalueofp53ki67andtlr5inneoplasticprogressionofbarrettsesophagusamatchedcasecontrolstudy
AT kauppilajoonash predictivevalueofp53ki67andtlr5inneoplasticprogressionofbarrettsesophagusamatchedcasecontrolstudy
AT karttunentuomoj predictivevalueofp53ki67andtlr5inneoplasticprogressionofbarrettsesophagusamatchedcasecontrolstudy
AT huhtaheikki predictivevalueofp53ki67andtlr5inneoplasticprogressionofbarrettsesophagusamatchedcasecontrolstudy